Study wrapper · #1174
Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.
Editor's note
The strength here is the source, a large randomized, placebo-controlled trial running 176 weeks, which is rare territory for obesity drugs. The limitation is that the endpoint is a Framingham risk equation, not actual cardiovascular events, and post hoc analyses of surrogate scores tend to run ahead of what outcome trials later confirm. The authors' cross-check against REWIND, where predicted and observed effects roughly agreed, is a reasonable credibility test, but the definitive answer awaits the event-driven SURMOUNT-MMO trial. Several authors are affiliated with the manufacturer, which readers should weigh.
Plain-language abstract
In a follow-on analysis of the 3-year SURMOUNT-1 trial, people with obesity and prediabetes on tirzepatide 15 mg saw their calculated 10-year heart-disease risk fall, while the placebo group's calculated risk rose. The authors stress these are modeled risk scores, not counted heart events, and that dedicated outcome trials are still needed.